Related Experiment Videos
Complications associated with sentinel lymph node biopsy for melanoma
William R Wrightson1, Sandra L Wong, Michael J Edwards
1Division of Surgical Oncology, Department of Surgery, University of Louisville, James Graham Brown Cancer Center, Kentucky, USA.
Annals of Surgical Oncology
|July 4, 2003
Summary
Sentinel lymph node (SLN) biopsy for melanoma staging is linked to fewer complications than completion lymph node dissection (CLND). This study found SLN biopsy alone has significantly less morbidity, offering a safer approach for patients.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Sentinel lymph node (SLN) biopsy is standard for melanoma staging.
- Limited data exists on SLN biopsy morbidity compared to completion lymph node dissection (CLND).
Purpose of the Study:
- To evaluate and compare the morbidity associated with SLN biopsy versus SLN biopsy plus CLND in melanoma patients.
Main Methods:
- Prospective data collection from the Sunbelt Melanoma Trial involving 2120 patients.
- Complications from SLN biopsy alone were compared to those from SLN biopsy followed by CLND.
Main Results:
- 4.6% of patients (96/2120) experienced complications after SLN biopsy alone.
- 23.2% of patients (103/444) had complications after SLN biopsy plus CLND.
- No procedure-related deaths occurred.
Conclusions:
- Sentinel lymph node biopsy alone is associated with significantly lower morbidity compared to completion lymph node dissection.